Company Overview and News
Dividend growth investing is a popular model followed by the investing community to build assets. Companies which not only pay dividends, but raise them year after year have been shown to perform better overall for investor returns.
LRCX CP PAG PSX KGI.DB QBCRF BMO 1128 CP AAPL CAH KL LEG WYNN KGI KGI.DB.A OTEX BMO WYNMF OTC NTAP TU QBCAF WYNMY
Artificial intelligence (AI) technology is being increasingly used in many industries, including the auto sector. In order to support its data-analysis processes, the Japanese auto giant Toyota Motor Corporation (TM - Free Report) has taken the decision to partner with ALBERT Inc., a data-driven and analytical data-solution firm. This collaboration will aid Toyota in the development of automated driving technologies.
PAG TM TYT HOG TOYOF MGA GM.WS.A GM.WS.B MG GM.WS.C 7203 GM GM.WSB AAP TTD SMG
PAG 8K - Annual Meeting and Dividend
Much to the delight of its shareholders, Penske Automotive Group, Inc. (PAG - Free Report) declared a hike in second-quarter 2018 cash dividend by around 2.9% to 35 cents per share. In the past year, the company has hiked dividend by approximately 12.9%. The increased dividend will be paid on Jun 1, 2018, to shareholders of record as of May 21, 2018. Notably, the company emphasizes on capital deployment and for that, it engages in share buybacks and hikes in dividend payment.
GNTX OSK PAG
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
SGMS ECOL EVH PSX FITBI AEE NOC ES SRCL DKS HSC COF-P MDR JACK OA EXPD MNESP CZR TRI MSFT APLS MGM WFC.PRL CTXS WFC.PRJ LB MATX NVDA BAX CLH COF-D WFC.PRT MGRC COF-C VRX CBTX COF-F WFC.PRR WFC.PRQ WFC.PRP AGN WFC.PRO WFC.PRN AAPL KO TSG WFC.PRY FIS WFC.PRX WFC.PRW LEG WFC.PRV CBS WLDN EA KLH MCHP GSK RHT IFRX GRPN TSCO ALLY SRE SBUX ENS NPO BYD LRCX AZN XOM COF.WS KEY ASND SOGO AN ALLY.PRA TFX CATO GSK CVA FLOW BKE VRX SC BRK.A CTS GOOGL LNN SBOT FITB COHU PFE COF.PRG WFCNP COF.PRH WWW YELP PAG OGS COF.PRP GPI WIMHY MYL MCB COF.PRC COF.PRD NEE DIS FEDU COF.PRF WFC LFUS WFC.WS WIMHF F COST MSA COF LECO WMH BMRN NEE.PRI NEE.PRJ SRE.PRA AZN BKNG ZG MRK NEE.PRC NEE.PRQ NEE.PRR
PAG Form 10-Q March 31, 2018 Table of Contents
The past week saw several important auto companies including Genuine Parts Company (GPC - Free Report) , PACCAR Inc. (PCAR - Free Report) , Harley-Davidson Inc. (HOG - Free Report) , Penske Automotive Group, Inc. (PAG - Free Report) and Ford Motor Company (F - Free Report) reporting their quarterly numbers. While Ford, Penske Automotive, Harley-Davidson and PACCAR beat on earnings, Genuine Parts Company missed the estimate.
PAG TM TYT PCAR HOG TOYOF GM.WS.A GM.WS.B GM.WS.C 7203 GM GM.WSB AAP
Shares of Penske Automotive Group, Inc. (PAG - Free Report) gained more than 4% in a day’s trading following its first-quarter fiscal 2018 earnings release. During the quarter, the company recorded adjusted earnings of $1.25 per share, which surpassed the Zacks Consensus Estimate of $1.12. Including tax benefits, net earnings came in at $1.26 per share. The company recorded net earnings of 97 cents per share in the year-ago quarter.
FOXF PAG ALSN
Penske Automotive Group, Inc. (NYSE:PAG) Q1 2018 Earnings Conference Call April 25, 2018 2:00 PM ET
The following slide deck was published by Penske Automotive Group, Inc. in conjunction with their 2018 Q1 earnings call.
PAG 8-K Q1 2018 Earnings UNITED STATES SECURITIES AND EXCHANGE C
The investment scenario has turned topsy-turvy of late, with no respite in sight. Tensions between two of the world’s biggest economies aggravated after Trump asked U.S. Trade Representatives to locate options to impose another $100 billion in tariffs on China products. Although the effective date of tariff implementation has not been decided yet, a fresh bout of uncertainty is about to spook the Wall Street.
FCN CNXN IMKTA PAG PCCC M NSIT
21h - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
Silicon Investor Message Boards
This table lists all message boards related to PAG / Penske Automotive Group, Inc. on message board site Silicon Investor.
as of ET